Pratia Pardubice a.s. — Clinical Trial Site

49 Registered trials

8 Currently recruiting

Organisation

Pratia Pardubice a.s.

Location

Pardubice I, Czechia

Identifier

ORG-100042222

Address

Trida Miru 2800, Zelene Predmesti, 530 02, Czechia

Departments

#40009
2108: CCR Czech a.s.
704_NA
7301
Ambulantní péče v oboru hematologie a transfúzní péče
cardiology
Chronic pain
Clinical Trials
CZ10003
Dermatology
Dermatovenerology
Klinicke hodnoceni
n/a
NA
neurology
Pardubice-centrum klinického hodnocení
Pratia Pardubice a.s.
Pratia s.r.o.,Třída Míru 2800,53002 Pardubice
Rheumatology

Clinical trials at this site (49)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised

2024-520302-19-00 Atopic dermatitis 4
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy… Pending

2024-514388-24-00 Knee osteoarthritis 4
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending

2024-520117-50-00 Atopic Dermatitis 4
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A Study to Learn About the Study Medicine Called PF-08049820 in People With Eczema, an Itchy Skin Rash Pending

2025-522965-31-00 Atopic Dermatitis 4
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting

2025-522440-41-00 Hidradenitis Suppurativa 4 2026-04-27
A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2… Recruiting

2025-521936-12-00 Adults with Type 2 Diabetes and/or Metabolic Syndrome 5 2026-04-24
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Ended

2025-523974-18-00 Obesity 5 2026-04-30
A Study of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis (BROADEN2) Ended

2025-522370-36-00 Moderate to Severe Atopic Dermatitis 4 2026-02-02
A Study Evaluating BFB759 in Atopic Dermatitis Ended

2025-521624-30-00 Atopic dermatitis 4 2026-01-08
A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis Ended

2025-522113-35-00 Atopic dermatitis 4 2026-01-07
SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended

2025-521791-63-00 Moderately to Severely Active Rheumatologic Disease 4 2025-12-18
A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended

2024-519370-40-00 Alopecia areata 5 2025-07-16
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Ended

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 as an Adjunct to Diet and Exercise in Ob… Ended

2024-517264-27-00 Obesity 4 2024-12-13
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25